Home > News > Latest > Cyclacel Pharmaceuticals Announces That Full Results from the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH Annual Meeting

Cyclacel Pharmaceuticals Announces That Full Results from the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH Annual Meeting

Cyclacel Pharmaceuticals, Inc. (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases.